Search

Aldosterone and eplerenone are mineralocorticoid receptor antagonists with one of the main roles in the treatment of heart failure, as demonstrated by large randomized controlled trials. Effects on patient outcomes are the result of blocking the renin-angiotensin-aldosterone system, which improves cardiac remodeling. Besides heart failure, mineralocorticoid receptor antagonists are used in treatment of patients with resistant arterial hypertension. This review focuses on the pharmacokinetics, pharmacodynamics, clinical effects, and safety profile of eplerenone. [ABSTRACT FROM AUTHOR]

Krka has over 25 years of experience in the production of high-quality medicines acting on the renin-anigotensin-aldosterone system (RAAS) and has become one of the leading producers of them in Europe. Since its first introduction of a medicine acting on RAAS it has been performing international clinical studies in order to monitor the efficacy and safety of its products within the scope of the doctrine, enable doctors to gain their own experience with them, and prove their efficacy and safety in clinical practice. With the findings of the studies described in this article, we would like to present the contribution of Krka's RAAS-acting medicines in the treatment of hypertension in over 25 years. [ABSTRACT FROM AUTHOR]